2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart…

By S. Wann, A. Curtis, C. January, K. Ellenbogen, J. Lowe, N. Estes, R. Page, M. Ezekowitz, D. Slotwiner, W. Jackman and 24 more. Circulation, 2011

1,012 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. (2014, neutral): “A majority of the writing group, 10 of 14 (71.4%), 67,68 Class III Antiarrhythmic medication therapy with class I agents is not recommended for the treatment of arrhythmias associated with CS.”
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. (2014, neutral): “Fibrillation” (5) and the 2 subsequent focused updates from 2011 (6, 7).”
Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). (2013, result): “These results were reflected in the 2011 American College of Cardiology Foundation/American Heart Association/ Heart Rhythm Society focused update on the management of AF patients, which assigned a Class IIB recommendation to the addition of clopidogrel in warfarin-ineligible patients (20).”